NOR is a rare inheritable polyagglutination phenomenon that has been described in two families. Our recent studies on these erythrocytes showed they contained at least two unique neutral glycosphingolipids, and based on their reactivity with Griffonia simplicifolia IB4 (GSL-IB4) isolectin (Kusnierz-Alejska, G., Duk, M., Storry, J. R., Reid, M. E., Wiecek, B., Seyfried, H., and Lisowska, E. (1999) Transfusion 39, 32-38), both oligosaccharide chains terminated with an ␣-galactose residue. The reactivity with GSL-IB4 suggested that these oligosaccharide chains terminated with a Gal␣133Gal-sequence and that anti-NOR agglutinins were common human anti-Gal␣133Gal xenoantibodies. In this report we describe the structure of one NOR component (NOR1) that migrated on thinlayer chromatographic plates in the region of pentaglycosylceramides. Treatment of this sample with ␣-galactosidase and ␤-N-acetylhexosaminidase was followed by highperformance thin-layer chromatography with product detection by lectins and the anti-Gb 4 monoclonal antibody. The results suggested that NOR1 was an ␣-galactosylated Gb 4 Cer with a ␤-N-acetylhexosaminidase-resistant GalNAc residue. Gas phase disassembly by ion trap mass spectrometry analysis showed the sequence to be Hex134HexN133Hex134Hex134Hex linked to a ceramide composed of C 18 sphingosine and a C 24 monounsaturated fatty acid. Together these data indicate NOR1 to be a novel Gal␣134GalNAc␤133Gal␣134Gal␤134 Glc-Cer structure. Additionally it has been shown that NOR glycolipids are recognized by human antibodies that were distinct from the known anti-Gal␣133Gal xenoantibodies.
Human sera contain many "natural" anti-carbohydrate antibodies directed against structures absent on the cells of the host or present in a cryptic form. Polyagglutination of erythrocytes occurs when an unusual structure is exposed on the cell surface and is recognized by antibodies commonly present in human sera. Polyagglutination may be transiently acquired by the exposure of cryptic carbohydrate structures due to the action of microbial enzymes (TF, Tk, Th, and others) persistently acquired, e.g. by reversible repression of galactosyltransferase in the Tn syndrome, or may be related to inherited genetic alterations leading either to impaired biosynthesis of normal glycans (hereditary erythroblastic multinuclearity associated with a positive acidified serum test) or to the appearance of a new structure on the erythrocyte surface (cold agglutinin disease) (1) . Carbohydrate antigens responsible for polyagglutination are also characterized by specific patterns of interaction with lectins (1) .
The first case of an inheritable NOR polyagglutination was reported by Harris et al. in 1982 (2) . Using a panel of lectins, the authors identified a new type of polyagglutination that was enhanced after treatment of NOR erythrocytes with proteases and was inhibited by sheep hydatic cyst fluid or avian P1 substance. Recently a second case of NOR polyagglutination has been identified in a two-generation Polish family (3) . We found that polyagglutination of NOR erythrocytes, besides having the features described by Harris et al. (2) , was enhanced by sialidase and abolished by ␣-galactosidase treatment. Several lines of evidence were obtained indicating that NOR erythrocytes possessed unique neutral glycosphingolipids. The agglutination of NOR erythrocytes was inhibited by a neutral glycosphingolipid fraction from NOR erythrocytes but not from control erythrocytes. High-performance thin-layer chromatography (HPTLC) 1 of neutral glycosphingolipids from NOR erythrocytes showed the presence of two bands that strongly stained with the isolectin IB4 isolated from Griffonia simplicifolia (GSL-IB4). This lectin did not react with any glycolipid from blood group-compatible (A2) control erythrocytes. A faster migrating GSL-IB4-positive band was also detected with Ricinus communis agglutinin I (RCA-I) which also strongly stained paragloboside in control and NOR erythrocytes (3) . The strong reactivity of the NOR glycolipids with GSL-IB4, which reacts preferably with the Gal␣133Gal-sequence (4), suggested the NOR erythrocytes contain glycolipid components that terminated with this structure. The Gal␣133Gal␤134GlcNAc-structure is abundantly expressed in glycoproteins and glycolipids of nonprimate mammals and New World monkeys and is not present in Old World monkeys, apes, and humans (5), but xenoantibodies specific for this structure are present in all human sera and are one of major reasons for a hyperacute rejection of xenotransplants (5, 6) . These data suggest that NOR-positive individuals could synthesize the Gal␣133Gal-terminating oligosaccharide chain and that anti-NOR agglutinins are the common anti-Gal␣133Gal antibodies.
The experiments described in this report were undertaken to find direct evidence for this hypothesis. The object of our study was to structurally identify the faster migrating NOR component separated by HPTLC that we have called NOR1. The results strongly suggest that NOR1 does not possess a Gal␣133Gal epitope but is a galactosylgloboside containing a linear pentaglycosidic chain terminated with a novel Gal␣134GalNAc-sequence. Moreover, it was shown that anti-NOR agglutinins are distinct from the known antiGal␣133Gal antibodies and may represent a new class of anti-carbohydrate antibodies present in human sera.
EXPERIMENTAL PROCEDURES
Erythrocytes-The blood of a healthy NOR-positive person (T.S.) (100 ml) was donated, and the red blood cells were serologically typed as A2, MNss, P1. The blood group N antigen was located on the variant St a glycophorin, which was accidentally found to be present in this family and not related to the NOR phenotype (3). The control blood samples (and human sera) were obtained from the Regional Center of Blood Transfusion in Wroclaw. The blood was taken into an anticoagulant solution.
Isolation of Glycosphingolipids-Neutral glycosphingolipids were isolated from lyophilized membranes of human NOR and control erythrocytes and rabbit erythrocytes as described previously (3) . Briefly the procedure included two chloroform/methanol (2:1 and 1:2, v/v) extractions, treatment of the extracted and evaporated material with 0.2 M KOH in methanol to remove phospholipids, desalting the neutralized samples on the Sephadex G-25 superfine (Amersham Pharmacia Biotech) column, and separation of neutral glycolipids from gangliosides on the DEAE-Sephadex A-25 (Amersham Pharmacia Biotech) column. The neutral glycolipids used in the present work were additionally purified by acetylation with acetic anhydride in pyridine (2:1) and fractionated on the Florisil (Fischer Scientific) column. The glycolipid fractions were deacetylated with 0.2 M KOH in methanol, neutralized, and desalted on the Sephadex G-25 superfine column (7) .
The neutral glycolipids from NOR and rabbit erythrocytes were fractionated on the Kieselgel H type 60 (Merck) 25-ml column in chloroform. Glycolipids, dissolved in 200 -300 l of chloroform/methanol/ water (55:45:10, v/v), were applied to the column and eluted with the same solvent. Fractions of ϳ1 ml were collected, and 3-4-l aliquots of each fraction were analyzed by HPTLC. The fractionated components were detected by orcinol staining and by means of GSL-IB4. This procedure was sufficient to purify rabbit pentaglycosylceramide (rGalnLc 4 Cer) but did not separate the NOR1 glycolipid fraction from tetraglycosylceramides.
The column fractions containing NOR1 were pooled, dried, and further purified by preparative TLC. The samples were applied to the HPTLC plates in 10-cm linear bands; the rGal-nLc 4 Cer (migrating similarly as NOR1) and Gb 4 Cer were applied on both sides. After development with chloroform/methanol/water (55:45:10, v/v), the middle part of the HPTLC band was covered with a glass plate, and both sides were sprayed lightly with the solution of 0.1% primuline in acetone/water (4:1, v/v). Gb 4 Cer and rGal-nLc 4 Cer were visualized with ultraviolet light. The glycolipids were extracted with chloroform/methanol/water (1:1:0.1, v/v) from the unstained part of the plate corresponding to the position of rGal-nLc 4 Cer. For an improved separation of Gb 4 Cer and nLc 4 Cer, the preparative TLC was repeated. The samples eluted from the TLC plate were passed through the Sephadex G-25 superfine column in chloroform/methanol/water (60:30:4.5, v/v) and dried. The described procedures were also applied for the purification of Gb 4 Cer and nLc 4 Cer, which were used as reference compounds.
Treatment of Glycosphingolipids with Glycosidases-The general procedures of Ostrander et al. (8) were used with modifications. Green coffee bean ␣-galactosidase was purified as described previously (9) , and jack bean ␤-N-acetylglucosaminidase was obtained from Sigma. This latter material had enzymatic activity toward GalNAc, and in this report we identify this preparation as ␤-N-acetylhexosaminidase. The glycolipid samples were solubilized in 50 l of chloroform/methanol (2:1, v/v) and mixed with 100 l of 1% sodium deoxytaurocholate solution in 1:1 chloroform/methanol. The total volume was dried under nitrogen in a conical-bottom tube. For ␣-galactosidase treatment of NOR1 fractions, the samples were sonicated in 100 l of 0.1 M citrate buffer (pH 4.9) for 5 min at 37°C and treated with 100 l of 0.05 M citrate/phosphate buffer (pH 6.0) containing 0.5 units of ␣-galactosidase. The samples were stirred for 62 h at 37°C and supplemented with 100 and 50 l of the enzyme solution after 20 and 45 h of incubation, respectively. Treatment with 50 l (0.25 units) of the galactosidase solution for 22 h was sufficient for galactose release when using rGalnLc 4 Cer as a substrate. Treatment with ␤-N-acetylhexosaminidase was performed in a similar way except using 0.2 M citrate buffer (pH 4.5) during sonication and incubation with 1.5 units of the enzyme for 46 h. The control samples were treated identically with respective buffers instead of enzyme solutions. Following incubation, the samples and controls were extracted with 5 volumes of chloroform/methanol (2:1, v/v), vortexed, and centrifuged, and the lower phase was withdrawn and dried under a nitrogen stream. The samples were dissolved in a chloroform/methanol/water (30:60:8, v/v) solution and applied to the DEAESephadex A-25 column prepared and packed using the same solvent. The eluted glycolipids were dried under a nitrogen stream.
Monoclonal Antibodies and Lectins-The murine monoclonal antibodies HJ6 anti-Gb 4 (10) and Gal-13 anti-Gal␣133Gal (11) were kindly provided by Dr. M. H. Nahm (Rochester, NY) and Dr. U. Galili (Chicago, IL), respectively. Lectins RCA-I and GSL-IB4 (both from Sigma) were biotinylated as described previously (12) .
Isolation of Human Anti-Gal␣133Gal Antibodies-Porcine erythrocyte glycophorin was prepared by the phenol extraction of membranes (13) . The glycophorin was coupled to CNBr-activated Sepharose 4B (Amersham Pharmacia Biotech) with the yield of 640 g (of 1 mg applied)/1 ml of Sepharose. Human AB group serum (90 ml), inactivated for 30 min at 56°C, was diluted 1:1 with 0.02 M phosphate buffer, 0.15 M NaCl, pH 7.5 (PBS) and passed through the 10-ml affinity column (10 ml/h) at room temperature. The column was washed with PBS, and the bound protein was eluted with 0.5 M galactose in PBS. Fractions (1.6 ml) were dialyzed against PBS and monitored for their ability to agglutinate rabbit erythrocytes with the most active fractions pooled (10.5 ml). The protein concentration was ϳ50 g/ml. This solution agglutinated rabbit erythrocytes up to a 1:256 dilution and did not agglutinate NOR erythrocytes. The purified antibodies were stored in the presence of 1% bovine serum albumin and 0.05% sodium azide at 4°C.
Isolation of Human Anti-NOR Agglutinins-The packed NOR erythrocytes (2 ml) were suspended in 12 ml of cold PBS. Six ml of cold PBS containing 40 l of 25% glutaraldehyde (Serva, Heidelberg, Germany) was added dropwise with mixing, and the suspension was left at room temperature for 30 min. The erythrocytes were centrifuged, exhaustively washed with PBS, mixed with 2 ml of human serum (blood group AB), and incubated for 90 min at room temperature. After centrifugation, the erythrocytes were washed again and treated twice with 2 ml of 0.5 M galactose in PBS for 1 h. During all incubations the erythrocyte suspensions were occasionally vortexed. The erythrocytes were centrifuged, and the combined eluates were dialyzed against PBS at 4°C and concentrated by ultrafiltration to a volume of 1 ml. This solution agglutinated papain-treated NOR erythrocytes at the titer 32-64 and did not agglutinate untreated or papain-treated rabbit erythrocytes. The anti-NOR antibodies were stored in the presence of 1% bovine serum albumin and 0.05% sodium azide at 4°C. The glutaraldehyde-fixed erythrocytes were washed several times with PBS and reused for antibody adsorption from the next serum samples.
HPTLC Lectin and Antibody Assays-The glycolipid samples, solubilized in chloroform/methanol (2:1, v/v), were applied to HPTLC plates (Kieselgel 60, Merck) and developed with chloroform/methanol/water (55:45:10, v/v). For the detection of glycolipids with lectins or antibodies (14) , the plates were dried, immersed in 0.05% polyisobutylmetacrylate (Aldrich) in n-hexane for 1 min, and dried. The plates were subsequently sprayed with TBS (0.05 M Tris buffer, 0.15 M NaCl, pH 7.4) and immersed in 2% bovine serum albumin in TBS for 1 h. To detect the glycolipids with lectins, the plates were overlaid successively with (i) biotinylated lectin, 5 g/1 ml of TBS containing 0.05% Tween 20 (TBS-T) for 1 h; (ii) ExtrAvidin-alkaline phosphatase conjugate (Sigma) diluted 1:4000 with TBS-T for 1 h; and (iii) a substrate solution of nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (Sigma). The plates were washed with TBS after each incubation. The immunostaining with antibodies was done similarly, but instead of biotinylated lectins, the plates were overlaid with mouse or human antibody solutions and then with biotinylated goat antibodies against mouse Ig (Dako, Glostrup, Denmark) or human Ig (Sigma) diluted with TBS containing 1% bovine serum albumin. The plates were incubated with the primary antibody for 2.5 h at room temperature, except for mAb HJ6 there was an overnight incubation at 4°C. Human antibodies, isolated as described above, were diluted 3ϫ with TBS-T.
Methylation-Glycolipid methylation was achieved by dissolving samples in a suspension of NaOH/Me 2 SO prepared by vortex-mixing Me 2 SO and powdered sodium hydroxide (15) . After 1 h at room temperature, 50 g of methyl iodide was added, and the suspension was incubated for 1 h at room temperature with occasional vortexing (16) . The methylated product was back-extracted by adding 1 ml of chloroform, and the suspensions were washed four times with 2-3 ml of 30% acetic acid. Methylated samples were dried following chloroform extraction and were stored at Ϫ20°C. The samples were redissolved to a concentration of 10 M in a 1 mM solution of sodium acetate in 70:30 methanol/water just prior to analysis.
Electrospray Ionization Mass Spectrometry-Mass measurements were performed with an ion trap mass spectrometer (model LCQ, Finnigan-MAT, San Jose, CA) equipped with electrospray ionization (17) . Samples were dissolved in methanol/water solutions (6:4, v/v) containing 0.25 mM NaOH and analyzed by syringe pump flow injection (1.5 l/min) directly into the electrospray chamber. Ions were injected axially into the ion trap by a gate lens, and a trapping field was established with a 100 -1100 kHz radio frequency applied to the ring electrode.
RESULTS

Preparation of NOR Glycosphingolipid Samples-
The total neutral glycosphingolipid fraction isolated from NOR erythrocytes was fractionated on the silica gel column, and the fractions containing NOR1 were pooled and further purified by preparative HPTLC. For enzymatic experiments, the preparative HPTLC step was repeated to ensure complete elimination of tetraglycosylceramides, which were abundant in human erythrocytes. The obtained samples were still heterogeneous and contained several components migrating in the eluted area. However, the NOR1 glycolipid could be distinguished by specific reactions with lectins or antibodies, and ion trap analysis ensured it to be free of contaminating material by stepwise isolation and molecular disassembly (MS n ). Immunochemical Characterization of NOR1-Our previous data (3) suggested that NOR glycolipids terminate with a Gal␣133Gal-sequence. Therefore, it seemed likely that NOR1 was formed by addition of ␣-galactose to nLc 4 Cer to give the structure Gal␣133Gal␤134GlcNAc␤133Gal␤134Glc␤1-Cer. A glycosphingolipid corresponding to this structure was known to be a major component of rabbit erythrocytes (18) ; thus, this material was purified from rabbit erythrocyte membranes to serve as a standard reference compound.
NOR1 and the rabbit glycolipid rGal-nLc 4 Cer migrated similarly on HPTLC plates, and both reacted with the GSL-IB4 and RCA-I. However, treatment of NOR1 and rGal-nLc4Cer with the coffee bean ␣-galactosidase clearly indicated the glycolipids to be different. The rGal-nLc 4 Cer TLC band, detected with RCA-I, disappeared after ␣-galactosidase treatment, and as expected, the nLc 4 Cer band, also detectable with RCA-I, was identified as the reaction product (Fig. 1) . The NOR1 was also degraded with ␣-galactosidase, but higher enzyme concentrations and longer incubation times were required. Moreover, no RCA-I-stained band was detected as a product (Fig. 1) . Furthermore, the mAb Gal-13 (anti-Gal␣133Gal) reacted strongly with rGal-nLc 4 Cer on the TLC plate, while no detectable reac- tion was noted with NOR1 (not shown).
To examine the possibility that NOR1 could be a galactosylated Gb 4 Cer, the anti-Gb 4 monoclonal antibody HJ6 was used. This antibody detected Gb 4 Cer in the NOR sample and also in control erythrocyte glycolipids. In addition, HJ6 reacted distinctly with NOR1 (Fig. 2 ). In the partially purified NOR1 sample the mAb HJ6 detected the NOR1 component and showed weaker reactivity with an additional slower migrating component. Treatment of this preparation with ␣-galactosidase gave total transformation of the NOR1 component into Gb 4 Cer, while the additional HJ6-positive band remained unchanged (Fig. 2) . These results strongly suggested that NOR1 was an ␣-galactosylated Gb 4 Cer. To examine how the ␣-galactose residue was attached to Gb 4 , the NOR1 sample was treated with ␤-N-acetylhexosaminidase. After this treatment the NOR1 band was still detectable with the GSL-IB4 (Fig. 3 ) and mAb HJ6 (not shown), while the enzyme totally degraded Gb 4 Cer under identical conditions. The inability of ␤-hexosaminidase to release a GalNAc residue on NOR1 suggested that an ␣-galactose moiety may be linked to the terminal GalNAc residue of Gb 4 Cer.
Mass Spectrometry Analysis of NOR1-HPTLC-purified NOR1 and rGal-nLc 4 Cer extracts were methylated, and each was analyzed by electrospray ionization ion trap mass spectrometry. The samples provided the full scan spectra in the two left panels (Fig. 4) . Higher resolution of the major ion in each spectrum (m/z 1776.3 and 1774.1) indicated they were singly charged and differed by 2 Da (Fig. 4, right panels) . Doubly charged ions were also observed at lower mass (m/z 899.4 2ϩ and 898.6 2ϩ ) (data not shown). Selection, activation, and fragmentation of the singly charged parents (MS 2 ) provided a simple product ion spectrum dominated by an identical oligosaccharide fragment, m/z 1116.7 ( Fig. 5, NOR1; Fig. 6 , rGalnLc 4 Cer from rabbit RBCs). Thus, the common oligosaccharide mass indicated that the 2 Da difference in the parent ion was FIG. 4 . Comparative study of rabbit and NOR1 RBC fractions by ion trap mass spectrometry (left panels). Higher resolution of the molecular weight-related ions (zoom scan) indicating the components to be singly charged (right panels). The 2 Da mass difference between the rabbit RBC and NOR1 sample was shown to be a feature of the ceramide fatty acid moiety (Fig. 7) . ITMS, ion trap mass spectrometry.
FIG. 5. Isolation and MS
2 of the singly charged NOR1 parent ion, m/z 1775.7. Product ions represent an intact pentasaccharide (m/z 1116.7) and a series of minor glycosidic fragments (see structure). The released ceramide fragment was only detected at high amplification (m/z 658.6, inset) and with inadequate abundance to study further by MS n . In contrast, doubly charged parents provided abundant ceramide product ions, and this precursor ion was used to detail the ceramide structure (see Fig. 7 ). associated with unsaturation in the ceramide moiety. The rabbit sample did show a unique and facile loss of the nonreducing terminal trisaccharide, m/z 1106.9 (Fig. 6) . Enhanced rupture proximal to aminosugar residues has been long recognized, and in this case the products were observed as a neutral loss from the parent ( t Gal-Gal-GalN) and sodiated product ion, m/z 690. 4 . In contrast to the singly charged parent ion, resonance activation of the doubly charged species provided abundant ceramide ions (cf. Fig. 6 ). It is probable that the second sodium enhances the probability of ceramide adduction and thus detection. These ceramide product ions were selected and activated to ascertain the C 24 monounsaturated fatty acid amide conjugated to a C 18 sphingosine (Fig. 7) .
The oligosaccharide related mass, m/z 1116.7, from each sample suggested a composition of four hexoses and a single aminosugar. To confirm this expectation each ion, m/z 1116.7 (NOR1 and rGal-nLc 4 Cer), was activated, and their product ion spectra were compared (Fig. 8) . Although the spectra share common fragments, it was clear that their linear sequence was different. Immediately obvious were the terminal disaccharide ions that identified different nonreducing termini, m/z 445.2 ( t Hex-Hex) and m/z 486.2 ( t Hex-HexN), from rGal-nLc 4 Cer and NOR1, respectively. However, a coincident fragment was observed at the next higher residue, m/z 690, strongly suggesting an inverted sequence in the nonreducing terminal trisaccharide. Numerous other fragments support this positional inversion as shown by the neutral losses of one, two, and three residues, m/z 880, 653, and 449 (Fig. 8) . These fragments identified the penultimate residue in the NOR1 sample as a HexN (see Fig. 8, inset structures) . This was further supported by the common sequence ions from the reducing terminus in both samples, m/z 894 and 690, and a different value for the next monomer, e.g. m/z 445.2 versus m/z 486.2 (rGal-nLc 4 Cer and NOR1, respectively). To further detail the internal sequence in the NOR1 sample, the reducing terminal trisaccharide fragment, m/z 653.3 (Fig. 8) , was isolated and disassembled (Fig. 9) . The 74 Da loss indicated a free reducing terminus, and the corresponding loss of two neutral hexose units (m/z 449.1 and 244.8) strongly suggests the structure to be HO-Hex-Hex-Hex-OH. Amplification and scale expansion provides a better evaluation of the extensive detail in this spectrum. As an example, 4-O-linkages were identified at m/z 314.8 and m/z 519.1, the cross-ring fragments 88 Da higher than the usual glycosidic bond rupture (m/z 226.8 and m/z 431, respectively). Different linkages exhibit specific cross-ring cleavage ions (17) , and in this spectrum such fragments support a hexose trisaccharide with identical 134 linkages. Cross-ring fragments are usually of low abundance in full scan spectra but are readily observed when smaller oligomer ions are activated or when coupled with scale amplification (Fig. 9) . This approach was used with considerable specificity to characterize and contrast the linkage in two isobaric glycolipid samples, NOR1 and SSEA-3 (Fig. 10 ). 2 Each sample was disassembled, and the terminal disaccharide was isolated (MS 3 ). Resonance activation of this ion, m/z 486, and spectral comparison of the products (MS 4 ) (Fig. 11 ) clearly demonstrated a difference in linkage. These contrasting spectra show a major cross-ring cleavage fragment, m/z 329, for the NOR1 sample that was characteristic of 134 linkage. The 2 SSEA-3 is a mixture of epitopes defined by the monoclonal antibody MC631. This antibody, however, cross-reacts with GB 4 , globo-H, and GalGb4 (Gb5). The cross-reactivity was clearly described by Kannagi et al. (23) . Thus, SSEA-3 is not the same as GalGb4 (Gb5), and it is better to define the GalGb4 structure as IVGalGb4 or as Gb5. S.-I. Hakomori, Pacific Northwest Res. Institute, Seattle, personal communication. (Fig. 6A) . The ceramide components were ascertained by amide rupture indicating a C 18 sphingosine and a C 24 monounsaturated fatty acid. In the NOR1 product, with detection of a 2 Da higher mass, the fatty acid has been assumed to be a C 24 saturated moiety.
isobaric product from SSEA-3, 3 m/z 486, provided no comparable fragments but did provide a fragment indicating terminal group 3-O-elimination, a common characteristic with 133-linked moieties. Thus, isolation and activation of smaller fragments greatly enhances linkage information, and the location of each structural entity can be provided by noting the pathway of disassembly. Because all fragments are "thermalized" prior to dissociation their spectra are reproducible, e.g. energetically isolated from their parent. Thus, stepwise molecular disassembly to smaller structural components provides a reproducible measure of fine structure free from energy perturbations of neighboring groups.
This ion trap mass spectrometry strategy indicates the NOR1 sample to have the following oligosaccharide chain: Hex134HexN133Hex134Hex134Hex with all internal link- 3 We greatly appreciate the opportunity to compare the isomeric structure ␤133galactosylgloboside, an SSEA-3 antigen, that was kindly isolated and provide by Dr. Akihiro Ito at the behest of Professor Sen-itiroh Hakomori. The sample was previously isolated and characterized (24). . The sequence written above the structure summarizes the spectral findings indicating inversion of the third and fourth residues from the reducing end. The cross-ring cleavage in the center residue of the rabbit sample defines the Hex134HexN linkage, while in the NOR1 sample fragments a Hex134Hex linkage was identified between the third and fourth residues from the nonreducing terminus. Further structural details were available by stepwise disassembly MS n .
ages established by MS n . The ceramide moiety is composed of a C 18 sphingosine residue and a C 24 monounsaturated fatty acid.
Human Antibodies Reacting with NOR Glycosphingolipids-
The cross-reactivity of NOR glycolipids and Gal␣133Gal-terminated oligosaccharide chains with GSL-IB4 brought on the question whether human anti-Gal␣133Gal antibodies also recognize the NOR glycolipids. Thus, anti-Gal␣133Gal antibodies were purified from human serum by affinity chromatography on the Sepharose 4B-linked glycophorin obtained from porcine erythrocytes. This is a rich source of Gal␣133Gal-terminated oligosaccharide chains (20) . The anti-NOR agglutinins were isolated by adsorption to glutaraldehyde-fixed NOR erythrocytes and elution with galactose. The anti-Gal␣133Gal anti- bodies strongly stained the rGal-nLc 4 Cer on the TLC plate but did not react with NOR glycolipids (Fig. 12) , while the buffer eluate from the affinity column, containing unadsorbed antibodies, reacted weakly with the NOR glycolipids (not shown). Similarly the isolated anti-NOR antibodies reacted distinctly with the NOR glycolipids and did not react with the rGalnLc 4 Cer (Fig. 11) . These results provided direct evidence that unique glycolipids identified in NOR erythrocytes are responsible for binding of human anti-NOR agglutinins. Moreover, the results demonstrated that the oligosaccharide chains present in NOR glycolipids and those terminated with the Gal␣133Gal-structure are recognized by different human antibodies. DISCUSSION A unique glycosphingolipid (NOR1) present in polyagglutinable NOR erythrocytes and absent from control erythrocytes has been identified by mass spectrometry and immunochemical methods. Migration of NOR1 on the HPTLC plates and comparison with related structures suggested it to be a pentaglycosylceramide. This and a strong decrease of polyagglutinability after treatment of NOR erythrocytes with ␣-galactosidase (3) led us to believe that NOR1 possessed a nonreducing terminal ␣-galactose residue and was probably formed from one of the precursor tetraglycosylceramides (nLc 4 Cer or Gb 4 Cer) within human erythrocytes. One such pentaglycosylceramide is the P1 glycolipid IV 4 -Gal-␣-nLc 4 Cer, 4 existing in ϳ80% of normal erythrocytes of Caucasians (21) . Although the NOR polyagglutination is inhibited by P1 antigens of animal origin, a normal level of P1 antigen was found in the studied NOR erythrocytes, indicating that the NOR phenotype does not result from an overexpression of P1 (3). A strong reactivity of NOR1 with GSL-IB4 suggested a Gal␣133Gal-terminated structure, i.e. IV 3 -Gal-␣-nLc 4 Cer, but enzymatic treatment with ␣-galactosidase did not produce the expected nLc 4 Cer product. It is noteworthy that P1 glycolipid was expected to be present in the analyzed preparation and should give nLc 4 Cer as a product of de-␣-galactosylation. Therefore, the lack of detectable nLc 4 Cer not only indicated another structure of the NOR1 but also suggested that the content of P1 glycolipid must have been too low to give a detectable product of the enzymatic reaction. The product of NOR1 degradation with ␣-galactosidase was identified as Gb 4 Cer with anti-Gb 4 monoclonal antibody. This suggested NOR1 to be an ␣-galactosylated Gb 4 Cer. Resistance of NOR1 to ␤-N-acetylhexosaminidase suggested the attachment of ␣-galactose to the terminal GalNAc residue of Gb 4 Cer. A branched structure, e.g. attachment of ␣-galactose to the subterminal galactose residue of Gb 4 , resulting in increased resistance of the terminal GalNAc residue to ␤-Nacetylhexosaminidase, could not be ruled out by these methods. However, the latter interpretation was totally inconsistent with the results obtained by mass spectrometry.
A full structure of the NOR1 was elucidated by mass spectrometry using an ion trap instrument and multiple step analysis (MS n ). The spectra were consistent with a Gb 4 internal structure and indicated a galactose residue to be 134 linked at the terminal HexNAc residue of Gb 4 . The ␣-galactosidase activity to generate a product fully characterized as Gb 4 confirms the anomeric stereochemistry of the nonreducing terminus to be a unique Gal␣(134)GalN-disaccharide. Cross-ring fragments following resonance excitation (MS n ) support the linkage of the remaining tetrasaccharide to be consistent with that of Gb 4 .
From these combined results we conclude that NOR1 has the oligosaccharide chain Gal␣134GalNAc␤133Gal␣134Gal␤1 34Glc-linked to ceramide composed of the C 18 sphingosine and C 24 monounsaturated fatty acid. To our knowledge, this is a novel structure (IV 4 -␣-Gal-Gb 4 Cer) that has not been previously described.
The NOR polyagglutination is an inheritable feature, but the genetic background of NOR glycolipid formation is not known. NOR1 may arise in NOR-positive individuals by expression of a new galactosyltransferase or an alteration in a gene encoding one of existing galactosyltransferases that leads to expression of an enzyme with changed or broadened specificity. In contradiction to rabbit erythrocytes where nLc 4 Cer is absent due to total transformation into IV 3 -␣-Gal-nLc 4 Cer (18), NOR erythrocytes exhibit only a small portion of Gb 4 Cer to be ␣-galactosylated since no distinct difference in the content of Gb 4 Cer in NOR and control erythrocytes has been noticed. The structure of the NOR1 oligosaccharide chain is most likely limited to glycolipids because no GSL-IB4-positive components were detected among NOR erythrocyte membrane proteins subjected to SDS-polyacrylamide gel electrophoresis and lectin blotting.
The oligosaccharide chain of NOR1 is specifically recognized by natural human antibodies that do not react with Gal␣133Gal-terminated oligosaccharides. On the other hand, both structures react strongly with GSL-IB4. This is not surprising in view of the usually broader specificity of lectins compared with antibodies. Inhibition of NOR polyagglutination by P1 glycoproteins of animal origin may indicate a crossreactivity of anti-NOR agglutinins with the Gal␣134Gal-sequence. However, anti-NOR antibodies did not react with Gal␣134Gal-terminated glycolipids (P1 or globotriaosylceramide) of control or NOR erythrocytes. Anti-NOR antibodies may cross-react weakly with Gal␣134Gal or may recognize other unidentified structures in animal P1 glycoproteins. On the other hand, the presence of anti-Gal␣134Gal antibodies in human sera was reported, but the antibodies were not tested with erythrocyte glycolipids, and their relation to anti-P1 antibodies (present in P2 individuals forming ϳ20% of the Caucasian population) was not elucidated (22) . The exact specificity of anti-NOR antibodies remains to established. The common existence of anti-NOR antibodies in human sera suggests that a respective antigen must exist in nature. An anti-NOR antibody (human polyclonal or mouse monoclonal) with well defined specificity should be helpful in looking for the presence of NOR-related structures in eukaryotic and prokaryotic cells.
